Ivana Magovcevic-Liebisch

Ivana Magovcevic-Liebisch is currently the President, Chief Executive Officer & Director at Vigil Neuroscience, Inc. She is also an Independent Director at Acrivon Therapeutics, Inc. In addition, she serves as an Advisor at Atlas Venture Advisors, Inc. and as a Trustee at Suffolk University, the Museum of Science, and The Boston Ballet, Inc. Previously, Dr. Magovcevic-Liebisch held the position of Chairman at Absci Corp.
from 2021 to 2023.
She was the Director of Intellectual Property & Patent Counsel at Transkaryotic Therapies, Inc. from 1998 to 2001.
She served as an Independent Director at Spyre Therapeutics, Inc. from 2018 to 2023 and as an Independent Director at Beacon Therapeutics (USA), Inc. from 2014 to 2022.
Dr. Magovcevic-Liebisch was also a Director at Alivio Therapeutics, Inc. and the Chief Operating Officer & Executive Vice President at Dyax Corp.
from 2012 to 2013.
She held the position of Senior VP & Head of Global Business Development at Teva Pharmaceutical Industries Ltd.
from 2013 to 2017.
Additionally, she was the Chief Business Officer & Executive Vice President at Ipsen SA from 2018 to 2020 and the Executive VP, Chief Strategy & Development Officer at Axcella Health, Inc. from 2017 to 2018.
Dr. Magovcevic-Liebisch completed her undergraduate studies at Wheaton College (Illinois) in 1989.
She obtained her doctorate degree from Harvard Medical School.
She also earned a graduate degree from Suffolk University Law School in 1999.